Nephrology

GLP-1RA use lowered cardiovascular, kidney, and mortality risks in patients with lupus and diabetes

A large UK study has shown that novel biomarkers reflecting kidney damage, fibrosis, inflammation, and cardiovascular disease can predict kidney failure and all-cause mortality in chronic kidney disease (CKD) with accuracy similar to established clinical risk factors.

A pilot randomized trial found sodium bicarbonate therapy modestly improved cognitive scores in older patients with CKD and metabolic acidosis, though these gains weren’t significantly better than placebo.

Learn how EGF and UMOD levels may predict diabetic kidney disease progression, offering new tools for clinical risk assessment.

New research uncovers a potential kidney origin for Parkinson’s disease, challenging the idea that it begins in the brain and revealing a new disease pathway.

Presented at ERA 2025, this multicentre study identifies three immune subtypes of checkpoint inhibitor–induced nephritis, linking them to clinical outcomes and treatment responses.

A post-hoc analysis of the CANVAS trial reveals a dose-dependent cardiovascular benefit with canagliflozin in type 2 diabetes, while kidney protection appears consistent across doses.

Pegcetacoplan demonstrated a significant reduction in proteinuria and signs of kidney damage in patients with C3G or IC-MPGN and nephrotic-range proteinuria, according to VALIANT Phase 3 results.